Over- and under-prescribing, and their association with functional disability in older patients at risk of further decline in Germany – a cross-sectional survey conducted as part of a randomised comparative effectiveness trial

Claudia Salm1*, Julia Sauer1, Nadine Binder1, Aline Pfefferle1, Mario Sofroniou1, Gloria Metzner2, Erik Farin-Glattacker2, Sebastian Voigt-Radloff3,4 and Andy Maun1

Abstract

Background: Older patients at risk of functional decline are frequently affected by polypharmacy. This is associated with a further loss of independence. However, a relationship between functional disability and medications, such as ‘Potentially Inappropriate Medications’ (PIMs) and ‘Potential Prescribing Omissions’ (PPOs), as itemised for (de) prescribing in practice-orientated medication lists, has yet to be established.

Methods: As part of a randomised comparative effectiveness trial, LoChro, we conducted a cross-sectional analysis of the association between PIMs and PPOs measured using the ‘Screening Tool of Older Persons’ Prescription Criteria / Screening Tool To Alert to Right Treatment’ (STOPP/START) Version 2, with functional disability assessed using the ‘World Health Organization Disability Assessment Schedule 2.0’ (WHODAS). Individuals aged 65 and older at risk of loss of independence were recruited from the inpatient and outpatient departments of the local university hospital. Multiple linear regression analysis was used to model the potential prediction of functional disability using the numbers of PIMs and PPOs, adjusted for confounders including multimorbidity.

Results: Out of 461 patients, both the number of PIMs and the number of PPOs were significantly associated with an increase in WHODAS-score (Regression coefficients B 2.7 [95% confidence interval: 1.5-3.8] and 1.5 [95% confidence interval: 0.2-2.7], respectively). In WHODAS-score prediction modelling the contribution of the number of PIMs exceeded the one of multimorbidity (standardised coefficients beta: PIM 0.20; multimorbidity 0.13; PPO 0.10), whereas no significant association between the WHODAS-score and the number of medications was seen. 73.5% (339) of the participants presented with at least one PIM, and 95.2% (439) with at least one PPO. The most common PIMs were proton pump inhibitors and analgesic medication, with frequent PPOs being pneumococcal and influenza vaccinations, as well as osteoporosis prophylaxis.

*Correspondence: Claudia.salm@uniklinik-freiburg.de

1 Institute of General Practice / Family Medicine, Faculty of Medicine and Medical Center – University of Freiburg, Elsässerstraße 2n, 79110 Freiburg, Germany

Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
**Conclusions:** The results indicate a relationship between inappropriate prescribing, both PIMs and PPOs, and functional disability, in older patients at risk of further decline. Long-term analysis may help clarify whether these patients benefit from interventions to reduce PIMs and PPOs.

**Keywords:** inappropriate prescribing, potentially inappropriate medications, potential prescribing omissions, polypharmacy, multimorbidity, functional disability

**Background**

Prescribing appropriately is a major challenge in the medical care of older patients. The impact of polypharmacy, as well as of ‘Potentially Inappropriate Medications’ (PIMs), on adverse events has been widely studied with differing outcomes: polypharmacy, most often defined as the concurrent intake of five or more medications [1], is associated with frailty [2], hospitalisation [3] and mortality [4]. Excessive polypharmacy, that is, the intake of ten or more drugs, shows an association with reduced quality of life [5, 6]. Yet, PIMs reveal a less concise association with adverse health outcomes [7, 8]. Major instruments in identifying PIMs are the Beers Criteria [9] and the PIM-identifying criteria of the Screening Tool of Older Persons’ Prescription Criteria / Screening Tool To Alert to Right Treatment’ (STOPP/START) Version 2 [10], often referred to as ‘STOPP criteria’. A retrospective cohort study of more than 170,000 older patients in the United States confirmed the Beers Criteria [9] as well as the STOPP criteria [10] as having a modest capacity to predict adverse drug events and hospitalisations, with the STOPP Criteria performing slightly more accurately [11]. In a two-year prospective cohort study the prescription of more than one PIM was associated with decreased health-related quality of life [12]. Furthermore, polypharmacy with at least one medication listed in the Beer’s criteria, was found to be associated with a functional decline at hospital discharge and at three months following discharge [13].

It must be acknowledged that polypharmacy, as well as PIMs, are only avoidable to a certain extent [14, 15], often leaving the prescriber with no alternative [16]. At the same time, polypharmacy can go hand in hand with under-prescribing or, more specifically, with ‘Potential Prescribing Omissions’ (PPOs) [17] that can be measured using the PPO-identifying items of the STOPP/START criteria [10, 18]. A longitudinal study in New Zealand, differentiating between Māori and non-Māori octogenarians, found an association between PPOs and mortality at 36-month-follow up in the Māori-group [19]. In a small cross-sectional analysis with 110 older participants PPOs were found to be associated with frailty [20]. Furthermore, a prospective examination of under-prescribing in outpatients with cardiovascular disease, also confirmed an association with under-prescribing and frailty [21]. However, overall, under-prescribing appears to be less well-documented in the recent literature.

Functional disability can lead to growing dependence, reduced quality of life, increased health care costs and augmented mortality in older patients [22–25]. Hence, functional disability has become recognised as an important patient-related outcome measure in clinical trials [26].

This study aims to investigate a potential association between PIMs as well as PPOs and functional disability in older patients at risk of further decline. Furthermore, the investigation seeks to characterise the population being studied and to assess the frequencies of PIMs and PPOs in this population.

**Methods**

**Study design, setting and participants**

This cross-sectional analysis was conducted as part of the LoChro trial, a randomised comparative effectiveness trial, to evaluate the effects of a local, collaborative, stepped and personalised care management approach for older people with chronic diseases and at risk of further functional decline in southern Germany [27]. People aged 65 years and older, at risk of further functional decline as indicated by a score of at least 2 of 6 points in the Identification of Older patients at Risk Screening Tool (ISAR) [28] were recruited from the inpatient and outpatient departments of the local university clinic between 2018 and 2020. The ISAR has demonstrated an association with unplanned readmissions, institutionalisation and the need for nursing care in older patients in Germany [29]. Exclusion criteria for the LoChro trial were: (1) terminal medical conditions, (2) lack of basic German-language skills or no German-speaking caregiver available and (3) not residing in the region [27].

**Variables and data sources**

The following section describes the baseline-variables of the LoChro trial that were relevant to the present cross-sectional analysis. Age, sex, family situation, living situation, education, health insurance status, number of hospital stays in last six months, ISAR-score and the score of the World Health Organization Disability Assessment Schedule 2.0 (WHODAS) were assessed through interviews that were conducted with the older
people and/or their family members or caregivers. Moreover, these interviews included a questionnaire asking for additional diagnoses relevant to the interpretation of the STOPP/START criteria Version 2.

Further diagnoses, medications, laboratory and other clinical parameters relevant to STOPP/START criteria Version 2 came from discharge letters, specialist reports in the case of outpatient visits, and other documents, such as laboratory results of the participating hospital. A team of two medical students, one junior and one senior practitioner, assessed diagnoses, medication, clinical data and the quality of available information. There was an expectation that the quality of data documented in the hospital system could vary. Thus, the quality of data available was allocated to two variables, with the expression “good” being used for current and complete diagnostic and medication data, and “sufficient” for data that included diagnostic and medication information documented in the six months prior to recruitment. Participants with no diagnostic or medication information in the last six months were excluded from the analysis.

Diagnostics were defined according to the International Classification of Diseases and related health problems, 10th revision (ICD-10) [30], medication according to the Anatomical Therapeutic Chemical (ATC) classification system [31].

Potentially Inappropriate Medication (PIMs), Potential Prescribing Omissions (PPOs), Multimorbidity and Functional Disability

PIMs and PPOs were defined by the STOPP/START criteria Version 2 [10]. Criteria that were not included were as follows: PIM A1, criteria that refer to the duration of treatment (PIM A2, H3,4,6) or treatment as first-line therapy (PIM B5,6, D2,12, F3, L1, PPO H1), and criteria that rely on special diagnostic issues due to a lack of differential information (PIM B7,9,12, D9,10, PPO A4, B3, C1,2,5, D2, E4,5, G1,2). PIM F2 was modified to “proton pump inhibitors without ongoing indication” whilst PIM D15, “neuroleptics without psychosis”, completed the catalogue following consensus within the medical working group.

The importance of confounding by multimorbidity in medication research has long been acknowledged [32]. However, counting the number of diagnoses within the hospital documentation system, and adding self-reported diagnoses, as measures of multimorbidity, are prone to bias due to overestimation. A recent systematic review of tools to measure multimorbidity for drug research recommended the use of indices validated for the outcome of interest [33]. Based on this proposal, Tooth et al’s weighted multimorbidity index that is recommended for the outcome “activities of daily living” had been chosen to measure multimorbidity [34].

Functional disability was assessed by the World Health Organization Disability Assessment Schedule 2.0 (WHODAS) [35] combining the following criteria, validated in the German population: evaluation of cognition, mobility, self-care, relationship with others, life activities and participation in social life [36]. The WHODAS overlaps with common health-related quality of life measurements such as the Short Form Health Survey (SF-36) [37], and has been developed to provide a common measurement of disability, relying on the biopsychosocial model of the International Classification of Functioning, Disability and Health (ICF) [38, 39].

Statistical methods

This examination included the characteristics of the study population presented through means and standard deviations, or absolute numbers and percentages, where appropriate. Characteristics of the groups below or above the median number of ‘Potentially Inappropriate Prescribing’ (PIP) (i.e. PIM plus PPO) were also presented. However, crude comparison tests were dispensed with, in order to minimise alpha error and false inferences. The frequency of diagnosis according to ICD-10 as well as the most frequently occurring PIMs and PPOs were illustrated using bar charts. Prior to regression analysis, crude correlations between explanatory variables were examined in order to compile the full regression model. The main explanatory variables (number of PIMs and number of PPOs) and the outcome factor (WHODAS-score) were considered as linear variables. Potential influences on the number of PIMs and PPOs on functional disability were then evaluated using multiple linear regression modelling. Backward variable selection, in which irrelevant variables are gradually eliminated from the full model, helped to obtain a stable final model in which the regression coefficients are unbiased and the associated p-values and confidence intervals are valid. Associations between the main explanatory and outcome variables were adjusted for age, sex, family status, living situation, education, health insurance (private vs. statutory), the ISAR score, weighted multimorbidity, number of regular medications, number of hospital attendances during the last six months, and the quality of information available.

The site of recruitment (inpatient vs. outpatient department) and the method of reporting (self-reporting vs. carer-reporting) were not included in the model, due to their a priori relationship with the number of hospital stays during the last six months, and multimorbidity. In addition, the requirements for linear analysis were examined. Analyses were performed using the open-source software R.
Ethical considerations
All methods were performed in accordance with the relevant guidelines and regulations. Written informed consent was obtained from all participants or, if an individual had a legal representative, from the latter. The study was approved by the ethical committee of the University of Freiburg (Ethical vote 495/17).

Results
At the time of analysis 484 participants were recruited for the LoChro trial and underwent baseline assessment. Data of 23 participants had to be excluded from the analysis due to insufficient information on diagnoses and medication. Characteristics of the remaining 461 participants and the subgroups with the number of PIPs below or above median, are reported in Table 1.

The mean age was 77 (standard deviation [SD] 6.5) and 55% were female. Of the 461 participants only six (1.3 %) presented with no PIP. 122 (26.5%) had no PIM and 22 (4.8%) no PPO. On average participants received two PIMs (mean 1.7; SD 1.6; range 0-8) and would benefit from three more prescriptions (including vaccinations) (mean number of PPOs 2.8; SD 1.5; range 0-9). The mean WHODAS total score lay at 34.9 (SD 22.2) of 100.

Table 1  Characteristics of the study population and according to number of potentially inappropriate prescription below or above median

| Variable                                | All n = 461 | PIP ≥ 4 n = 274 | PIP < 4 n = 187 |
|-----------------------------------------|-------------|-----------------|-----------------|
| Age (years), m (SD)                     | 77 (6.5)    | 78 (6.5)        | 76 (6.4)        |
| Female, n (%)                           | 254 (55.1)  | 153 (55.8)      | 101 (54.0)      |
| Family situation, n (%)                 |             |                 |                 |
| Married                                  | 219 (47.5)  | 118 (43.1)      | 101 (54.0)      |
| Single                                   | 38 (8.2)    | 25 (9.1)        | 13 (7.0)        |
| Divorced                                 | 61 (13.2)   | 35 (12.8)       | 26 (13.9)       |
| Widowed                                  | 143 (31.0)  | 96 (35.0)       | 47 (25.1)       |
| Living situation, n (%)                 |             |                 |                 |
| Private household                       | 419 (90.9)  | 247 (90.1)      | 172 (92.0)      |
| Senior residencya                        | 37 (8.0)    | 23 (8.4)        | 14 (7.5)        |
| Retirement home or nursing home         | 5 (1.1)     | 4 (1.5)         | 1 (0.5)         |
| Education, n (%)                        |             |                 |                 |
| College qualification                   | 130 (28.3)  | 74 (27.0)       | 56 (30.1)       |
| Junior high school diploma              | 130 (28.3)  | 74 (27.0)       | 56 (30.1)       |
| Secondary school diploma                | 187 (40.7)  | 120 (43.8)      | 67 (36.0)       |
| No school degree                        | 13 (2.8)    | 6 (2.2)         | 7 (3.8)         |
| Statutory health insurance, n (%)       | 362 (78.9)  | 216 (79.1)      | 146 (78.5)      |
| ISAR, m (SD)                             | 2.8 (1.0)   | 3.0 (1.1)       | 2.6 (0.8)       |
| Multimorbidityb, m (SD)                 | 5.6 (3.6)   | 6.6 (3.8)       | 4.3 (2.8)       |
| No. of hospital stays in last six months, m (SD) | 0.8 (1.2) | 0.8 (1.2) | 0.7 (1.1) |
| Medications per participant, m (SD)      | 9.8 (4.5)   | 10.8 (4.5)      | 8.2 (4.1)       |
| PIM per participant, m (SD)              | 1.7 (1.6)   | 2.4 (1.6)       | 0.6 (0.7)       |
| PPO per participant, m (SD)              | 2.8 (1.5)   | 3.5 (1.4)       | 1.7 (0.9)       |
| Quality of information: good, n (%)     | 406 (91.4)  | 243 (92.0)      | 163 (90.6)      |
| Functional disability                   |             |                 |                 |
| WHODAS cognition, m (SD)                | 21.3 (23.3) | 25.1 (25.1)     | 15.8 (19.0)     |
| WHODAS mobility, m (SD)                 | 47.0 (32.2) | 54.3 (31.5)     | 36.4 (30.3)     |
| WHODAS self-care, m (SD)                | 25.6 (29.6) | 32.3 (31.2)     | 15.8 (24.0)     |
| WHODAS relationships, m (SD)            | 27.4 (26.8) | 32.0 (28.7)     | 20.5 (22.2)     |
| WHODAS life activities, m (SD)          | 51.7 (37.8) | 59.3 (36.5)     | 40.7 (37.1)     |
| WHODAS participation, m (SD)            | 40.0 (24.1) | 44.8 (24.1)     | 33.4 (22.5)     |
| WHODAS total score, m (SD)              | 34.9 (22.2) | 40.2 (22.7)     | 26.9 (19.8)     |

M Mean; SD Standard deviation; PIP Potentially inappropriate prescription; PIM Potentially inappropriate medication; PPO potential prescribing omission; ISAR Identification of Seniors at Risk Screening Tool; WHODAS World Health Organization Disability Assessment Schedule 2.0 (0: no disability; 100: maximal disability); a: senior residency: mainly independent living with minor nursing support; b: Multimorbidity as measured by the outcome-orientated multimorbidity score “Activities of daily life” (ADL) of Tooth et al [34].
possible points, with 0 points indicating no disability and 100 points maximal disability. The mean number of medications taken was eleven (SD 4.7; range 0-23, median 10). Only 53 (11.5%) participants took less than five medications. The study population presented a high amount of multimorbidity as indicated by an average score of 5.6 (SD 3.6) in Tooth’s multimorbidity index and 2.8 (SD 1.0) in ISAR. The average number of diagnoses per participant was 13 (SD 5.0; range 2-25, median 12); ten (SD 4.3) of these were documented in the hospital documentation system.

A more in-depth picture of the study population’s morbidity is shown in the stacked bar chart of diagnoses in Fig. 1: Here, the number of diagnoses in the whole study population for each ICD-10-class is illustrated and the percentage of patients with at least one diagnosis of each specific ICD-10-class is given.

Table 2  Multiple linear regression analysis modelling PIM and PPO on functional disability measured using the WHODAS total score (n= 410, final model after variable selection)

|                          | Reg. coeff. B | SE  | 95%-CI for B | Std. coeff. Beta | p-value |
|--------------------------|--------------|-----|--------------|------------------|---------|
| No. of PIM               | 2.65         | 0.57| 1.53; 3.76   | 0.20             | < 0.001 |
| No. of PPO               | 1.49         | 0.64| 0.24; 2.74   | 0.10             | 0.020   |
| ISAR                     | 5.27         | 1.01| 3.28; 7.25   | 0.24             | < 0.001 |
| Multimorbidity*          | 0.84         | 0.29| 0.26; 1.41   | 0.13             | 0.004   |
| No. of hospital stays in 6 m | 2.42     | 0.81| 0.82; 4.01   | 0.13             | 0.003   |
| Gender, female           | 6.55         | 1.82| 2.96; 10.13  | 0.31             | < 0.001 |
| Living independently     | -7.30        | 3.05| -13.30; -1.30| -0.35            | 0.001   |
| Quality of information: good | -9.67     | 3.25| -16.06; -3.27| -0.46            | 0.003   |

**WHODAS World Health Organization Disability Assessment Schedule 2 (with 0 points indicating no and 100 points indicating maximal functional disability); Reg. coeff. B Regression coefficient B; SE Standard error; CI Confidence interval; Std. coeff. Beta Standard coefficient Beta; PIM Potentially inappropriate medication; PPO Potential prescribing omission; ISAR Identification of Seniors at Risk Screening Tool. * Multimorbidity as measured by the outcome-orientated multimorbidity score “Activities of daily life” (ADL) of Tooth et al [32].

Fig. 1  Total number of diagnoses according to ICD-10 classes. The numbers above each column indicate the total number of diagnoses according to ICD-10 class; the percentage indicates for the proportion of individuals with at least one diagnosis of the specific ICD-10-class. Note: “Symptoms and abnormal findings” correspond to ICD-10 class XVIII (R00-R99) and include symptoms not belonging to a specified disease [30].
Frequent diseases within ICD-classes, such as ischaemic heart disease or hypertension, were marked separately. The top three ICD-10-classes were diseases of the circulatory system, musculoskeletal system and endocrine system. The most common diagnoses of the circulatory system were hypertension followed by ischaemic heart disease and atrial fibrillation. The most common diagnosis of the musculoskeletal system was osteoarthritis, whilst the most common endocrine disorder was Type II diabetes mellitus.

Figure 2 shows the frequencies of the PIMs and PPOs that occurred ten or more times in the study population. 17 PIMs were never observed in the population under study (PIM B2, B13, C1, C7, D6, D7, D11, E1, E2, E3, E5, F1, F4, G1, H8, J2, J6), 31 occurred one to ten times, only. PPO E7 was never observed and four PPOs (A2, B2, C6, D1) were observed between 1 and 10 times. The number one PIM was the prescribing of proton pump inhibitors without an ongoing indication. The most frequently reported prescribing omissions were pneumococcal and influenza vaccinations.

Participants with a number of inappropriate medications above median were more often older, female, widowed, divorced or single compared to other participants. On average, patients with more than three PIPs scored higher in the multimorbidity score and took more regular medication. Furthermore, subjects in the group of inappropriate medication above median presented a significantly higher degree of functional impairment than others, as measured by an average WHODAS-score of 40.5 (SD 22.7) compared to 26.9 (SD 18.8) (difference in means 13.6; 95%-confidence-interval [9.8; 17.4]; p-value < 0.0001).

Table 2 shows the results of the multiple linear regression analysis. After adjustment for all named possible confounders, the score of functional disability rose almost three points with one more PIM (regression coefficient B 2.7; 95%-confidence-interval 1.5 - 3.8), and 1.5 points with one more PPO (regression coefficient B 1.5; 95%-confidence-interval 0.2 – 2.7). Both associations were confirmed as statistically significant (p < 0.001 for PIM and p < 0.05 for PPO). The contribution of multimorbidity to the functional disability score was calculated as 0.8 (95%-confidence-interval 0.3-1.4; p < 0.005). Other significant contributors to functional disability were female sex, ISAR-scoring and number of hospital stays during the last six months. No significant contribution to the prediction of functional disability was observed for the number of medications. In total the model predicted 30% of the variance in functional disability (corrected R² 0.28).

Regarding multicollinearity, all variance inflation factors were less than 1.5, and tolerance was greater than 0.5 for all variables. Residua were not correlated and their normal distribution, linearity and homoscedasticity were given.

Discussion
In the present study of older patients at risk of functional decline, PIMs as well as PPOs demonstrated a significant association with functional disability. The modelled contribution of PIMs to the prediction of functional disability exceeded that of multimorbidity. Both, PIMs and PPOs contributed more to the prediction of the outcome than the number of medications.

Strikingly, PIMs and PPOs were common in the study population, with only six participants not experiencing any inappropriate prescribing according to STOPP/START criteria Version 2.

Interpretation and Comparison to other studies
These results reflect the selection of older patients at risk: The LoChro-Study addresses older, chronically ill individuals; hence, our study population shows a high level of morbidity. On average, those being studied had an ISAR score of 2.9 (over two points indicating “seniors at risk of functional decline”) and took eleven regular medications. 408 (88.5%) of the participants took five or more medications, thus, fulfilling a common criterion of polypharmacy [1]. In the recently published analysis of the Survey of Health, Ageing and Retirement in Europe (SHARE), which included people aged 65 and above, 31% presented with five or more medications [40]. The morbidity of our study population also appears in the high average number of diagnoses. To analyse the appropriateness of medication in the present study, hospital data and self-reported diagnoses were combined, which led to more diagnoses overall. However, of the average number of diagnoses documented in the hospital documentation system, ten (SD 4.3), appeared comparable to the seven to ten diagnoses found in a sample of older patients with similar inclusion criteria in an Australian study [41]. In a German telephone health interview survey from 2009, 35% of people aged 75 and above suffered five or more conditions [42]. In 2012, the mean number of self-reported diagnoses in those aged 70 and above were three to four [43]. Our results are therefore not representative of all older patients in the country. However, they may be representative of older patients at risk of functional decline in Germany. Finally, the degree of functional disability is high in the sample studied. With a mean WHODAS-score of 35 points the average study participant lies on the 90th percentile of the general population [35]. In conclusion, this survey deals with multimorbid, highly impaired, older patients.
The prevalence of PIMs and PPOs in this study are in accordance with other results: investigations into the prevalence of potentially inappropriate prescribing in acutely ill inpatients in six European hospitals found STOPP-listed PIMs in 35-77% participants and PPOs in 51-73% participants [44]. In a prospective study of under-prescribing in outpatients with cardiovascular disease in Germany, using STOPP/START V2 with a focus on cardiovascular medications alone, under-prescribing was common at 69% [21]. Furthermore, regarding the results of this study, the majority of participants were not vaccinated in accordance with national recommendations [45], osteoporosis prophylaxis was lacking, as well as medications for constipation and gout. Common PIMs referred

![Fig. 2 Frequencies of the potentially inappropriate medications (PIM) (above) and the potential prescribing omissions (PPO) (below) according to STOPP/START criteria version 2 [10] with a frequency above ten. PPI, proton pump inhibitor; la, long-acting; bt-pill, break-through-pill; AA, antplatelet agents; OAC, oral anticoagulants; imb, imbalances (here specifically: hypokalaemia, hyponatraemia, hypercalcaemia); IHD, ischaemic heart disease CVD, cerebrovascular disease; PVD, peripheral vascular disease; TCA, Ticyclic antidepressants; glc, glaucoma; CCA, cardiac conduction abnormalities; pro, prostatism; urinary retention; AF, atrial fibrillation; TIA, transient ischemic attack; DMARD, disease modifying antirheumatic drugs; XO, xanthine-oxidase-inhibitor; B2A, beta-2 agonist; AMC, antimuscarinic bronchodilatator; prostagl, prostaglandine; bb, betablocker; Alzheimer’s d., Alzheimer’s disease; appr, appropriate; HF, heart failure BPP, bisphosphonates. * High bleeding risk according to PIM C3 (STOPP/START criteria version 2 [10]): (documentation of) uncontrolled severe hypertension, bleeding diathesis, recent non-trivial spontaneous bleeding. ** PIM G3: Antimuscarinic bronchodilators with glaucoma or prostatism; PIM I1: Antimuscarinic drugs with dementia, glaucoma or prostatism; *** Type II or III heart block; **** unless the patient’s status is end-of-life or age is > 85 years.](image-url)
to the safe use of opioids, orthostatic hypotension and neuroleptics without diagnosis. These observations were similar to a previous examination in the same region of Germany; only the use of benzodiazepines, particularly the most common PIM, appeared to have decreased, possibly indicating a positive effect of educational campaigns [46]. Pneumococcal vaccination rates amongst people aged between 60 and 72 in the German study region was assumed to be 13% [47], lower than 23% in this study of older patients. A recently published German study on influenza vaccination rates in older patients found a registered vaccination rate of 29-39% in the years 2011-2018 [48], considerably lower than our self-reported one-point survey (60%). Reporter and memory bias, especially in the case of pneumococcal vaccinations, and the selection of older patients at risk, might have supported these differences.

General Practitioners report feeling insufficiently trained in dealing with impairment and frailty amongst their patients, and see their role as dependent on patient motivation, and on the broader public health setting [49, 50]. Practitioners recognise that in daily consultations with older patients, the emphasis lies mainly on prescribing [49]. Whilst polypharmacy is consistently associated with physical decline [51], a recent study of over 2,500 individuals aged 65 and above found no association between PIMs and functional impairment, measured by a change in the Barthel-index at three-month follow up [8]. PIMs measured by the Beer’s criteria were found to be associated with a functional decline, in contrast to PIMs measured using the STOPP criteria in an Italian study [13]. A prospective cohort study confirmed a negative influence of PIMs on health-related quality of life [12]. However, several tools to identify PIMs have been published in order to meet the needs of a specific country, as well as the drugs marketed and the local prescribing culture. There may therefore be discrepancies in the outcomes assessed [52]. Furthermore, most of these studies were carried out in populations of older patients, where the variance of risk of loss of independence within the study group was disregarded [3, 8, 12, 13, 17]. Moreover, information on PIMs or PPOs was partly dispensed with by integrating them as binary variables [3, 13, 17, 21].

The results of our study indicate that a linear association between PIMs and PPOs, and functional disability, exists in highly impaired older patients.

Notably, the clinical relevance of a 1.5 or 2.7 increase, on average, in WHODAS score for PPOs and PIMs respectively, is supported by the minimal variation in WHODAS-scoring in the general population [35]. Interestingly, the prediction of WHODAS-score could be better explained by the number of PIMs than by a rise in multimorbidity score. In addition, the contribution of the number of medications to the variation in WHODAS score remained insignificant after inclusion of PIMs and PPOs. The latter strengthens the notion that it is not the quantity of medication that matters most, but the appropriateness of prescribing in the older patient.

The Cochrane Central Register of Controlled Trials lists a trial, that hypothesises an effect of optimised prescribing on the level of functional autonomy [53]. The findings of our cross-sectional study support the hypothesis that older patients who are at risk might benefit from interventions to reduce inappropriate prescribing.

Strengths and limitations
A limitation of this study was that the cross-sectional design led to a more stable hypothesis, but it could not demonstrate a causal relationship. In addition, participants were recruited from different settings, so the quality of available data was diverse. However, this was controlled for in multiple linear regression analysis. Because not all STOPP/START criteria were used in the current study, the prevalence of PIP in the study population may have been underestimated. Furthermore, as medication lists originated partly from hospital discharge letters, the duration of medication effect on the patient needed to be considered. However, it was assumed that most of the over 4,500 prescribed medications in the study population had a prior influence on the participants.

The emphasis on older patients at risk of adverse outcomes acts as a strengthening factor between the chief explanatory and outcome variables. This study maintained a focus on older patients who had coped with polypharmacy, inappropriate medication and multimorbidity. Our results highlight how crucial appropriate prescribing is for such patients. In addition to information on diagnoses and relevant medication, laboratory results and further diagnostic parameters were also extracted, completing the picture of the morbidity of participants. To avoid a bias of over-diagnosis, a multimorbidity term was used to account for the possibility of confounding effects on the association of exposure and outcome variables. Finally, this study considers both PIMs and PPOs, thus presenting a holistic view of inappropriate prescribing and functional disability in the study population.

Conclusion
The results indicate that interventions into inappropriate and under-prescribing might offer the opportunity to directly improve functional ability in older patients at risk of loss of independence. The frequency and clarity of the study findings show that these are actionable results with direct implications for daily practice.
Abbreviations
ATC: Anatomical Therapeutic Chemical; SF-36: Short Form Health Survey;
ICF: International Classification of Functioning, Disability and Health; PIP: Potentially inappropriate Prescribing; SHARE: Survey of Health, Ageing and Retirement in Europe; br-pill: Break-through-pill; AA: Antiplatelets agents; OAC: Oral anticoagulants; Abn: Abnormalities; CHD: Coronary heart disease; PVD: Peripheral vascular disease; TIA: Transitory ischemic attack; DMARD: Disease modifying antirheumatic drugs; XO: Xanthine-oxidase-inhibitor; BPP: Bisphosphonates; Reg. coeff. B: Regression coefficient B; SE: Standard error; CI: Confidence interval; Std. coeff. Beta: Standard coefficient Beta.

Acknowledgements
The authors wish to thank all participants of the LoCho-Trial for their efforts spent in this research.

Authors’ contributions
CS, MS and AM wrote the main manuscript text; NB performed the statistical analyses, JS, AP, CS and AM collected data relevant to diagnoses and medication and analysed the appropriateness of medications; SVR, as conceptual head of the LoCho-Trial, was responsible for the recruitment of participants and the whole study management, while GM and EFG were responsible for data regarding the measurement of functional disability. All authors interpreted the data and read and approved the final manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL. The LoCho-Trial was funded by the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF).

Availability of data and materials
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
All methods were performed in accordance with the relevant guidelines and regulations. The study was approved by the ethical committee of the University of Freiburg (Ethical vote 495/17). All participants or their legal representatives gave written informed consent prior to participation in the study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Institute of General Practice / Family Medicine, Faculty of Medicine and Medical Center - University of Freiburg, Elisabethstraße 2n, 79110 Freiburg, Germany.
2Section of Health Care Research and Rehabilitation Research, Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg, Hugstetterstraße 49, 79106 Freiburg, Germany.
3Center for Geriatric Medicine and Gerontology Freiburg, Faculty of Medicine and Medical Center - University of Freiburg, Lehenstrasse 88, 79106 Freiburg, Germany.
4Institute for Evidence in Medicine, Faculty of Medicine and Medical Center - University of Freiburg, Breisacher Straße 153, 79110 Freiburg, Germany.

Received: 1 March 2022 Accepted: 23 June 2022
Published online: 07 July 2022

References
1. Khenezian M, McNeil CJ, Murray AD, Myint PK. An overview of prevalence, determinants and health outcomes of polypharmacy. Ther Adv Drug Saf. 2020;12: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244176/.
2. Veronesi N, Stubbs B, Noale M, Solmi M, Pilotto A, Vaona A. Polypharmacy Is Associated With Higher Frailty Risk in Older People: An 8-Year Longitudinal Cohort Study. J Am Med Dir Assoc. 2017;18(7):624–8.
3. Sganga F, Landi F, Ruggiero C, Corsonello A, Vetrano DL, Lattanzio F, et al. Polypharmacy and health outcomes among older adults discharged from hospital: Results from the CRIME study. Geriatr Gerontol Int. 2015;15(2):141–6.
4. Leelakanon N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: A systematic review and meta-analy‐sis. J Am Pharm Assoc. 2017;57(6):729–738.e10.
5. Montiel-Luque A, Núñez-Montenegro AJ, Martín-Aurioles E, Canca-Sánchez JC, Toro-Toro MC, González-Correa JA. Medication-related factors associated with health-related quality of life in patients older than 65 years with polypharmacy. PLoS One. 2017;12(2):e0171320.
6. Riekert A, Trampisch US, Klaßen-Melke R, Drewelow E, Esmail A, Johansson T. Polypharmacy in older patients with chronic diseases: a cross-sectional analysis of factors associated with excessive polypharmacy. BMC Fam Pract. 2018;18 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052592/.
7. Eno A, Eparasu RR. Healthcare Outcomes Associated with Beers’ Criteria: A Systematic Review. Ann Pharmacother. 2007,41(3):438–48.
8. De Vincenzi A, Gallo P, Finamore P, Pedone C, Costanzo L, Pasina L. Poten‑tially Inappropriate Medications, Drug–Drug Interactions, and Anticho‑linerergic Burden in Elderly Hospitalized Patients: Does an Association Exist with Post-Discharge Health Outcomes? Drugs Aging. 2020;37(8):585–93.
9. American Geriatrics Society. 2019 Updated AGS Beers Criteria® for Poten‑tially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674–94.
10. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8.
11. Brown JD, Hutchison LC, Li C, Painter JT, Martin BC. Predictive validity of the Beers and STOPP Criteria to detect adverse drug events, hospitalizations, and emergency department visits in the United States. J Am Geriatr Soc. 2016;64(1):22–30.
12. Wallace E, McDowell R, Bennett K, Fahey T, Smith SM. Impact of Poten‑tially Inappropriate Prescribing on Adverse Drug Events, Health Related Quality of Life and Emergency Hospital Attendance in Older People Attending General Practice: A Prospective Cohort Study. J Gerontol Ser A. 2017;73(2):271–7.
13. Fabbetti P, Ruggiero C, Sganga F, Fusco S, Mammarella F, Barbini N. Effects of hyperpolypharmacy and potentially inappropriate medications (PIMs) on functional decline in older patients discharged from acute care hospitals. Arch Gerontol Geriatr. 2018;77:158–62.
14. Wise J. Polypharmacy: a necessary evil. BMJ. 2013;347:f7033.
15. Cossette B, Ethier JF, Joly-Mischlich T, Bergeron J, Ricard G, Brazeau S. Reduction in potentially inappropriate medication use in elderly inpatients: a pragmatic randomized controlled trial. Eur J Clin Pharmacol. 2017;73(10):1237–45.
16. Anthierens S, Tansens A, Petrovic M, Christaens T. Qualitative insights into general practitioners’ views on polypharmacy. BMC Fam Pract. 2010;11(1):65.
17. Kuipers MAJ, van Marum RJ, Egberts ACG, Jansen PAF. OLDy (Old people Drugs & Dysregulations) Study Group. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol. 2008;65(1):130–3.
18. Ryan C, O’Mahony D, Byrne S. Application of STOPP and START criteria: interrater reliability among pharmacists. Ann Pharmacother. 2009;43(7):1239–44.
19. Cardwell K, Kerse N, Hughes CM, Teh R, Moyes SA, Menzies O, et al. Does potentially inappropriate prescribing predict an increased risk of admission to hospital or mortality? A longitudinal study of the ‘oldest old’. BMC Geriatr. 2020;20(1):1–9.
20. Guichérrez-Valencia M, Izquierdo ML, Jacalle-Fabio E, Marín-Epele J, Ramón-Espinoza MF, Domene-Domene T. Relationship between frailty, polypharmacy, and underprescription in older adults living in nursing homes. Eur J Clin Pharmacol. 2018;74(7):961–70.
21. Meid AD, Quinzler R, Holleczek B, Fagerström C. Malnutrition, functional ability and mortality among older people aged ≥ 60 years: a 7-year longitudinal study. Eur J Clin Nutr. 2016;70(3):399–404.
23. Tornero-Quíñones I, Sáez-Padilla J, Espina Díaz A, Abad Robles MT, Sierra Robles A. Functional Ability, Frailty and Risk of Falls in the Elderly: Relations with Autonomy in Daily Living. Int J Environ Res Public Health. 2020;17(3):1008.

24. Fagerström C, Borglin G. Mobility, functional ability and health-related quality of life among people of 60 years or older. Aging Clin Exp Res. 2010;22(5–6):387–94.

25. Kelso S, Mitchell S, Rowe PJ, Gore P. The Scottish national LifeCurve™ survey: costs of functional decline, opportunities to achieve early intervention to support well-being in later life, and meaningfulness of the LifeCurve™. Public Health. 2020;180:129–35.

26. Working Group on Functional Outcome Measures for Clinical Trials. Functional Outcomes for Clinical Trials in Frail Older Persons: Time To Be Moving. J Gerontol A Biol Sci Med Sci. 2008;63(2):160–4.

27. Frank F, Bjørregaard F, Bengel J, Bitzer EM, Heimbach B, Kaier K. Local, collaborative, stepped and personalised care management for older people with chronic diseases (LoChro): study protocol of a randomised comparative effectiveness trial. BMC Geriatr. 2019;4: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392457/.

28. McCusker J, Bellavance F, Cardin S, Trépanier S. Screening for geriatric problems in the emergency department: reliability and validity. Identification of Seniors at Risk (ISAR) Steering Committee. Acad Emerg Med. 1998;5(9):883–93.

29. Singer K, Herpner HJ, Skutetzky A, Seber C, Christ M, Thiem U. Predictive validity of the identification of seniors at risk screening tool in a German emergency department setting. Gerontology. 2014;60(5):413–9.

30. Organization WH. International classification of diseases and related health problems, 10th revision. http://www.who.int/classifications/apps/icd/icd11online/ [Internet]. 2007 https://cnniac.rand.org/10024668523/.

31. WHOCC - ATC/DDD Index [Internet].: https://www.whocc.no/ atc_ddd_index/.

32. Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical validation of the “World Health Organization Disability Assessment Schedule, WHODAS-II” in patients with chronic diseases. Health Qual Life Outcomes. 2010;8(1):51.

33. Stirland LE, González-Saavedra L, Mullin DS, Ritchie CW, Muniz-Terrera G, Russ TC. Measuring multimorbidity beyond counting diseases: systematic review of community and population studies and guide to index choice. BMJ. 2020;368:m160.

34. Tooth L, Hockley R, Byles J, Dobson A. Weighted multimorbidity indexes predicted mortality, health service use, and health-related quality of life in older women. J Clin Epidemiol. 2008;61(2):151–9.

35. Organization WH. Measuring Health and Disability: Manual for WHO Disability Assessment Schedule WHO-DAS II. World Health Organization; 2010. 145 S.

36. Pösl M, Cieza A, Stucki G. Psychometric properties of the WHODASII in patients with chronic diseases, 10th revision. J Rehabil Med. 2010;42(4):267–71.

37. Fuchs J, Busch M, Lange C, Scheidt-Nave C. Prevalence and patterns of morbidity among adults in Germany. Results of the German telephone health interview survey German Health Update (GEDA) 2009. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012;55(4):576–86.

38. Gallagher P, Lang PO, Cherubini A, Topinková E, Cruz-Jentoft A, Montero-Errasquin B. Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals. Eur J Clin Pharmacol. 2011;67(11):1175–88.

39. Robert Koch-Institut. Standige Impfkommission (STIKO) am RKI: Wissenschaftliche Begründung für die Aktualisierung der Pneumokokken-Impfpflicht für Senioren. 2016 http://edoc.rki.de/docviews.abstract.php?lang=en&id=4549

40. Endres HG, Kaufmann-Kolle P, Steeb V, Bauer E, Böttner C, Thürmann P. Association between Potentially Inappropriate Medication (PIM) Use and Risk of Hospitalization in Older Adults: An Observational Study Based on Routine Data Comparing PIM Use with Use of PIM Alternatives. PLoS One. 2016; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740421/.

41. Koch-Institut R. Epidemiologisches Bulletin 47/2020. November. 2020;34.

42. Sawicki OA, Müller A, Glushan A, Klaasen-Mielek R, Gerlach FM, Beyer M. Influenza-Impfquote in der älteren Bevölkerung in und außerhalb der HZV in Baden-Württemberg - Online ZFA. 05. 14. Mai. 2021,05(969):195.

43. Agerinou C, Korwani M, Gavana M, Andreou M, Papageorgiou DI, Roka V, et al. Perceptions, attitudes and training needs of primary healthcare professionals in identifying and managing frailty: a qualitative study. Eur Geriatr Med. 2021;12(2):321–32.

44. Ambagstshere RC, Archibald MM, Lawless M, Mills D, Yu S, Beilby JJ. General practitioners’ perceptions, attitudes and experiences of frailty and frailty screening. Aust J Gen Pract. 2019;48(7):426–33.

45. Katsimpris A, Linseisen J, Meisinger C, Volakis K. The Association Between Polypharmacy and Physical Function in Older Adults: A Systematic Review. J Gen Intern Med. 2019;34(9):1865–73.

46. Schiavo G, Forginni M, Lucchetta RC, Mastroianni P de C. A comprehensive look at explicit screening tools for potentially inappropriate medication: A systematic scoping review. Australasian Journal on Ageing https://onlinelibrary.wiley.com/doi/abs/10.1111/ajag.13046

47. Hospices Civils de Lyon. Optimization of Drug Prescribing in an Elderly Population of Geriatric Consultations and Living at Home [Internet]. clinicaltrials.gov; 2018. https://clinicaltrials.gov/ct2/show/NCT02740764

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.